Results 161 to 170 of about 5,026 (198)
Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis [PDF]
Journal of Controlled Release, 2016 We have recently discovered a specific Murine Double Minute 2 (MDM2) oncogene inhibitor, called SP141, which exerts potent anticancer activity in various breast cancer models. However, its low oral bioavailability is the major hurdle for moving this drug to clinical trial.
Jiang-Jiang Qin +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment
Journal of the Neurological SciencesChronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated demyelinating neuropathy that can lead to secondary axonal degeneration and irreversible weakness and disability. Early effective treatment is therefore necessary to minimize the degree of axonal degeneration.
Suraj Muley
exaly +3 more sources
Journal of Pharmaceutical Sciences, 2005
FcRn protects immune gamma globulin (IgG) from intracellular catabolism, and thereby contributes to the long plasma half-life associated with this class of antibody. The present study tested the hypothesis that 4C9, an anti-FcRn antibody, would increase the in vivo systemic clearance of a model antibody, anti-methotrexate IgG (AMI), in rats. Hybridomas
Kate E, Getman, Joseph P, Balthasar
openaire +2 more sources
FcRn protects immune gamma globulin (IgG) from intracellular catabolism, and thereby contributes to the long plasma half-life associated with this class of antibody. The present study tested the hypothesis that 4C9, an anti-FcRn antibody, would increase the in vivo systemic clearance of a model antibody, anti-methotrexate IgG (AMI), in rats. Hybridomas
Kate E, Getman, Joseph P, Balthasar
openaire +2 more sources
X-ray Crystal Structures of Monomeric and Dimeric Peptide Inhibitors in Complex with the Human Neonatal Fc Receptor, FcRn [PDF]
Journal of Biological Chemistry, 2010 The neonatal Fc receptor, FcRn, is responsible for the long half-life of IgG molecules in vivo and is a potential therapeutic target for the treatment of autoimmune diseases. A family of peptides comprising the consensus motif GHFGGXY, where X is preferably a hydrophobic amino acid, was shown previously to inhibit the human IgG:human FcRn protein ...
Vicki Nienaber
exaly +3 more sources
FcRn Inhibitor Therapies in Neurologic Diseases
CNS DrugsIn the last decade, the landscape of treating autoimmune diseases has evolved with the emergence and approval of novel targeted therapies. Several new biological agents offer selective and target-specific immunotherapy and therefore fewer side effects, such as neonatal Fc receptor (FcRn)-targeting therapy.
Nouf Alfaidi +3 more
openaire +2 more sources
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
Neurological SciencesImmunoglobulin G (IgG) autoantibodies can lead to the formation of autoimmune diseases through Fab and/or Fc-mediated interactions with host molecules as well as activated T cells. The neonatal Fc receptor (FcRn) binds at acidic pH IgG and albumin, and the mechanism for prolonging serum IgG half-life is making IgG re-entry into circulation by prompting
Yun Yang +4 more
openaire +2 more sources
FcRn inhibitors: A new era in neurotherapeutics
The neonatal Fc receptor (FcRn) is a heterodimeric protein that binds albumin and immunoglobulin G (IgG) to mediate pH-dependent recycling, prevent degradation, and maintain their serum concentrations. The ability to bind IgG means FcRn plays both beneficial and potentially detrimental roles in host immunity.James F, Howard, Jeffrey T, Guptill
openaire +2 more sources
Cytokine
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts, leading to bleeding risks. Despite existing treatments, many patients with chronic or refractory ITP remain inadequately managed. Fc-receptors, including neonatal Fc receptor (FcRn), play a crucial role in the ITP pathogenesis by activating antibody-dependent ...
Mohammad Ali, Nilforoushzadeh +5 more
openaire +2 more sources
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts, leading to bleeding risks. Despite existing treatments, many patients with chronic or refractory ITP remain inadequately managed. Fc-receptors, including neonatal Fc receptor (FcRn), play a crucial role in the ITP pathogenesis by activating antibody-dependent ...
Mohammad Ali, Nilforoushzadeh +5 more
openaire +2 more sources
FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases
Autoimmunity ReviewsPathogenic IgG autoantibodies play a crucial role in the pathogenesis of autoimmune diseases, and removal of pathogenic IgG autoantibodies is an important therapeutic approach and tool for such diseases. The neonatal Fc receptor (FcRn) interacts with IgG and protects it from lysosomal degradation.
Lina, Zhu, Lanjun, Li, Jun, Wu
openaire +2 more sources
Journal of Neurology
Myasthenia gravis (MG) is an autoimmune disease that causes local or generalized muscle weakness. Complement inhibitors and targeting of the neonatal Fc receptor (FcRn) to block IgG cycling are two novel and successful mechanisms.PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were systematically searched to identify relevant studies ...
Jiaxuan Li +7 more
openaire +2 more sources
Myasthenia gravis (MG) is an autoimmune disease that causes local or generalized muscle weakness. Complement inhibitors and targeting of the neonatal Fc receptor (FcRn) to block IgG cycling are two novel and successful mechanisms.PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were systematically searched to identify relevant studies ...
Jiaxuan Li +7 more
openaire +2 more sources